Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience Buys 1,739,130 Shares

Biodesix, Inc. (NASDAQ:BDSXGet Rating) Chairman John Patience purchased 1,739,130 shares of the company’s stock in a transaction on Monday, November 21st. The stock was purchased at an average price of $1.15 per share, for a total transaction of $1,999,999.50. Following the purchase, the chairman now directly owns 4,550,483 shares of the company’s stock, valued at approximately $5,233,055.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Biodesix Price Performance

NASDAQ BDSX opened at $1.30 on Tuesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.64 and a quick ratio of 0.64. The firm has a market capitalization of $54.72 million, a PE ratio of -0.75 and a beta of 1.14. Biodesix, Inc. has a 12 month low of $0.96 and a 12 month high of $7.20. The company’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.64.

Biodesix (NASDAQ:BDSXGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). The firm had revenue of $11.11 million during the quarter, compared to analyst estimates of $10.90 million. Biodesix had a negative return on equity of 723.65% and a negative net margin of 162.97%. As a group, equities research analysts forecast that Biodesix, Inc. will post -1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BDSX. Allworth Financial LP bought a new position in shares of Biodesix during the 2nd quarter valued at $92,000. Renaissance Technologies LLC bought a new position in shares of Biodesix during the 2nd quarter valued at $93,000. Endurant Capital Management LP bought a new position in Biodesix in the 1st quarter worth $221,000. Vanguard Group Inc. lifted its position in Biodesix by 33.1% during the 3rd quarter. Vanguard Group Inc. now owns 239,656 shares of the company’s stock worth $305,000 after acquiring an additional 59,660 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in Biodesix during the 3rd quarter worth $480,000. Institutional investors own 53.48% of the company’s stock.

Biodesix Company Profile

(Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Recommended Stories

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.